ESMO Virtual Plenary 2022: Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation 16 Mar 2022 The ICR strongly welcomes new findings that the targeted drug olaparib improves survival in women with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide
ESMO 2021: Immunotherapy combination could be alternative to ‘Extreme’ chemotherapy in some head and neck cancers 11 Oct 2021 An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests. Find out more Show/Hide
ESMO 2021: Drug combination shows promise in treatment-resistant advanced ovarian cancer 19 Sep 2021 A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients. Find out more Show/Hide
ESMO 2020: Research breakthrough offers new hope for high risk patients with HR+ breast cancer 20 Sep 2020
ESMO 2020: Step forward in treatment for patients with newly diagnosed advanced ovarian cancer 18 Sep 2020
ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men with advanced prostate cancer 30 Sep 2019
ESMO 2019: Modern chemotherapy drug better than second targeted hormone therapy against resistant prostate cancer 30 Sep 2019
ESMO 2019: Largest ever trial in postoperative prostate cancer patients confirms that men can be spared radiotherapy after surgery 27 Sep 2019